A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adult Subjects With Friedreich Ataxia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2018
At a glance
- Drugs TAK 831 (Primary)
- Indications Friedreich's ataxia
- Focus Therapeutic Use
- Sponsors Takeda
- 28 Sep 2018 Planned End Date changed from 27 Feb 2019 to 4 Jan 2019.
- 28 Sep 2018 Planned primary completion date changed from 27 Feb 2019 to 4 Jan 2019.
- 28 Sep 2018 Status changed from recruiting to active, no longer recruiting.